Literature DB >> 29937207

Multimodality imaging guidance for percutaneous paravalvular leak closure: Insights from the multi-centre FFPP register.

Sébastien Hascoet1, Grzegorz Smolka2, Francois Bagate3, Julien Guihaire4, Agathe Potier4, Khaled Hadeed5, Yoan Lavie-Badie6, Hélène Bouvaist7, Claire Dauphin8, Fabrice Bauer9, Mohammed Nejjari10, Remy Pillière11, Eric Brochet12, Lionel Mangin13, Guillaume Bonnet14, Vlad Ciobotaru15, Guillaume Leurent16, Najib Hammoudi17, Adel Aminian18, Clement Karsenty19, Christian Spaulding20, Sebastien Armero21, Frederic Collet22, Didier Champagnac23, Julien Ternacle24, Martin Kloeckner4, Benoit Gerardin4, Marc-Antoine Isorni4.   

Abstract

BACKGROUND: Percutaneous paravalvular leak (PVL) closure has emerged as a palliative alternative to surgical management in selected high-risk patients. Percutaneous procedures are challenging, especially for mitral PVL. Accurate imaging of the morphologies of the defects is mandatory, together with precise guidance in the catheterization laboratory to enhance success rates. AIMS: To describe imaging modalities used in clinical practice to guide percutaneous PVL closure and assess the potential of new imaging tools.
METHODS: Data from the 'Fermeture de Fuite paraprothétique' (FFPP) register were used. The FFPP register is an international multi-institutional collaborative register started in 2017 with a retrospective and a prospective part. A descriptive analysis of multimodality imaging used to guide PVL closure in clinical practice was performed.
RESULTS: Data from 173 procedures performed in 19 centres from three countries (France, Belgium and Poland) were collected, which included eight cases of PVL following transcatheter valve replacement. Transoesophageal echocardiography was used in 167 cases (96.5%) and 3D echocardiography in 87.4% of cases. In one case, 3D-echocardiography was fused with fluoroscopy images in real time using echonavigator software. Details about multimodality imaging were available from a sample of 31 patients. Cardiac computed tomography (CT) was performed before 10 of the procedures. In one case, fusion between preprocedural cardiac CT angiography data and fluoroscopy data was used. In two cases, a 3D model of the valve with PVL was printed.
CONCLUSION: Echocardiography, particularly the 3D mode, is the cornerstone of PVL imaging. Other imaging modalities, such as cardiac CT and cardiac magnetic resonance imaging, may be of complementary interest. New techniques such as imaging fusion and printing may further facilitate the percutaneous approach of PVLs.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  3D echocardiography; 4D-flow MRI; Cardiac valve; Echocardiographie 3D; Fuite paraprothétique; IRM 4D flow; Paravalvular leak; Valve cardiaque

Mesh:

Year:  2018        PMID: 29937207     DOI: 10.1016/j.acvd.2018.05.001

Source DB:  PubMed          Journal:  Arch Cardiovasc Dis        ISSN: 1875-2128            Impact factor:   2.340


  5 in total

1.  Aggravating dyspnea in a 62-year-old man.

Authors:  Maryam Shojaeifard; Shirin Habibi Khorasani; Zahra Rahnamoun
Journal:  J Echocardiogr       Date:  2021-02-24

2.  Paravalvular Leak Echo Imaging before and during the Percutaneous Procedure.

Authors:  Piotr Pysz; Wojtek Wojakowski; Grzegorz Smolka
Journal:  J Clin Med       Date:  2022-06-01       Impact factor: 4.964

Review 3.  EDUCATIONAL SERIES IN CONGENITAL HEART DISEASE: Three-dimensional echocardiography in congenital heart disease.

Authors:  John M Simpson; Annemien van den Bosch
Journal:  Echo Res Pract       Date:  2019-05-13

4.  Computational Fluid Dynamics Simulations of Mitral Paravalvular Leaks in Human Heart.

Authors:  Krzysztof Wojtas; Michał Kozłowski; Wojciech Orciuch; Łukasz Makowski
Journal:  Materials (Basel)       Date:  2021-11-30       Impact factor: 3.623

5.  3D-Printing to Plan Complex Transcatheter Paravalvular Leaks Closure.

Authors:  Vlad Ciobotaru; Victor-Xavier Tadros; Marcos Batistella; Eric Maupas; Romain Gallet; Benoit Decante; Emmanuel Lebret; Benoit Gerardin; Sebastien Hascoet
Journal:  J Clin Med       Date:  2022-08-15       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.